Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE HYDROCHLOROTHIAZIDE AND RESERPINE versus HYDRALAZINE HYDROCHLORIDE HYDROCHLOROTHIAZIDE RESERPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE HYDROCHLOROTHIAZIDE AND RESERPINE versus HYDRALAZINE HYDROCHLORIDE HYDROCHLOROTHIAZIDE RESERPINE.
HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE vs HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting vasodilator that relaxes arterial smooth muscle, reducing peripheral vascular resistance. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, decreasing plasma volume and cardiac output. Reserpine depletes catecholamines from adrenergic nerve endings, reducing sympathetic tone and lowering blood pressure.
Hydralazine directly relaxes arteriolar smooth muscle by unclear mechanism, possibly interfering with calcium movements; hydrochlorothiazide inhibits the Na+/Cl- cotransporter in distal convoluted tubules, reducing reabsorption of sodium and chloride; reserpine depletes catecholamines from adrenergic nerve endings by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow.
Oral: 1 tablet (containing 25 mg hydralazine hydrochloride, 25 mg hydrochlorothiazide, and 0.1 mg reserpine) twice daily. Maximum dose: 2 tablets twice daily.
1 tablet (25 mg hydralazine / 25 mg hydrochlorothiazide / 0.1 mg reserpine) orally once daily, increased to 2 tablets daily if needed.
None Documented
None Documented
Hydralazine: 3-7 hours (terminal; prolonged in renal impairment; acetylator phenotype affects clearance; slow acetylators have higher AUC). Hydrochlorothiazide: 6-15 hours (terminal; prolonged in renal impairment, up to 24 h in severe dysfunction). Reserpine: 50-100 hours (terminal; biphasic with α-phase 4.5 h; prolonged in liver disease).
Hydralazine: 3-7 h (slow acetylators) or 1-2 h (rapid acetylators); Hydrochlorothiazide: 6-15 h; Reserpine: 50-100 h (biphasic, terminal half-life).
Hydralazine: 90% renal (as metabolites, 5-10% unchanged), 10% fecal. Hydrochlorothiazide: >95% renal (unchanged). Reserpine: 30-50% renal (as metabolites), 40-60% fecal (unchanged and metabolites).
Hydralazine: 80% renal, 5% fecal; Hydrochlorothiazide: >95% renal; Reserpine: 60% renal, 40% fecal.
Category A/B
Category A/B
Antiaderenergic
Antiaderenergic